biotech
Exit Opportunities for Biotech Investors: US vs Europe
Filed in archive Corporate and Industrial News by ruth on August 30, 2005
BlogPicture

In an article published recently in Nature's Bioentrepreneur, a comparison of initial public offerings (IPOs) and trade sale exits through mergers and acquisitions (M&A) seems to suggest that biotech prospects are shifting to Europe.
... second-quarter European biotech IPO volume was the strongest it's been since 2000. All told, in the first half of 2005, European IPO proceeds actually topped those in the US, reaching nearly $500 million, debunking yet another myth about relative exit opportunities across the Atlantic. In fact, the average value of biotech IPOs in Europe is rising. This year the average proceeds hit $40 million, more than twice what they were just two years ago. By comparison, biotech proceeds in the US have remained level at around $60 million.


Read the full article here.

Permalink: Exit Opportunities for Biotech Investors: US vs Europe
Tags: biotech  IPO  europe  exit  opportunities  exit+opportunities  biotech+investors  investors+europe 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/8828
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Exit Opportunities for Biotech Investors: US vs Europe:

  • Currently 8.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.00 out of 1 vote(s) cast.
 
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!